Surrozen reports developments as a clinical-stage biotechnology company developing Wnt-based targeted therapeutics for sight-threatening ophthalmic diseases. Company updates center on its ophthalmology pipeline, including SZN-8141 and SZN-8143 in retinal diseases, antibody-engineering work, financial results, collaboration and license revenue, and research milestones tied to Boehringer Ingelheim.
Recurring announcements also cover healthcare investor conference presentations, Nasdaq inducement equity grants under the 2025 Equity Inducement Plan, and corporate governance or leadership matters that affect the company's public-company reporting profile.
Surrozen Inc. (Nasdaq: SRZN) has announced that CEO Craig Parker will present a company overview and business update at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. ET. Interested parties can access the live webcast on Surrozen's website, with a replay available afterward.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, with applications in inflammatory bowel disease, hepatitis, eye diseases, and more. For further details, visit surrozen.com.